Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
19.5M
-
Shares change
-
+481K
-
Total reported value, excl. options
-
$132M
-
Value change
-
+$4.78M
-
Put/Call ratio
-
0.3
-
Number of buys
-
52
-
Number of sells
-
-39
-
Price
-
$6.79
Significant Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q2 2023
107 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2023.
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.5M shares
of 45.1M outstanding shares and own 43.24% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.53M shares), VANGUARD GROUP INC (2.23M shares), Sofinnova Investments, Inc. (2.19M shares), Polar Capital Holdings Plc (2.1M shares), D. E. Shaw & Co., Inc. (1.28M shares), STATE STREET CORP (745K shares), GEODE CAPITAL MANAGEMENT, LLC (712K shares), ACADIAN ASSET MANAGEMENT LLC (654K shares), JACOBS LEVY EQUITY MANAGEMENT, INC (565K shares), and Nuveen Asset Management, LLC (425K shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.